Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection.
Proc Natl Acad Sci U S A
; 120(11): e2219523120, 2023 03 14.
Статья
в английский
| MEDLINE | ID: covidwho-2262238
ABSTRACT
The continuous evolution of SARS-CoV-2 variants complicates efforts to combat the ongoing pandemic, underscoring the need for a dynamic platform for the rapid development of pan-viral variant therapeutics. Oligonucleotide therapeutics are enhancing the treatment of numerous diseases with unprecedented potency, duration of effect, and safety. Through the systematic screening of hundreds of oligonucleotide sequences, we identified fully chemically stabilized siRNAs and ASOs that target regions of the SARS-CoV-2 genome conserved in all variants of concern, including delta and omicron. We successively evaluated candidates in cellular reporter assays, followed by viral inhibition in cell culture, with eventual testing of leads for in vivo antiviral activity in the lung. Previous attempts to deliver therapeutic oligonucleotides to the lung have met with only modest success. Here, we report the development of a platform for identifying and generating potent, chemically modified multimeric siRNAs bioavailable in the lung after local intranasal and intratracheal delivery. The optimized divalent siRNAs showed robust antiviral activity in human cells and mouse models of SARS-CoV-2 infection and represent a new paradigm for antiviral therapeutic development for current and future pandemics.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
COVID-19
Тип исследования:
Экспериментальные исследования
/
Систематический обзор/метаанализ
Темы:
Варианты
Пределы темы:
Животные
/
Люди
Язык:
английский
Журнал:
Proc Natl Acad Sci U S A
Год:
2023
Тип:
Статья
Документы, близкие по теме
MEDLINE
...
LILACS
LIS